# CUE-101 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cue-101

> CUE-101, sponsored by Cue Biopharma, Inc. (CUE): 8 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CUE-101 |
| Codes | CUE-101 |
| Sponsor | Cue Biopharma, Inc. (CUE) https://sec-api.dev/companies/cue/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track |

## Timeline

### September 30, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0000950170-24-127005): "As of September 30, 2024, two of these milestones had been achieved, as we had filed an investigational new drug application, or IND, in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000095017024127005/cue-20240930.htm

### December 31, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-03-31, last confirmed 2025-03-31.
- SEC Form 10-K (accession 0000950170-25-047677): "As of December 31, 2024, two of these milestones had been achieved, as we had filed an investigational new drug application, or IND, in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000095017025047677/cue-20241231.htm

### March 31, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-05-12, last confirmed 2025-05-12.
- SEC Form 10-Q (accession 0000950170-25-069125): "As of March 31, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000095017025069125/cue-20250331.htm

### June 30, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-08-12, last confirmed 2025-08-12.
- SEC Form 10-Q (accession 0000950170-25-107270): "As of June 30, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000095017025107270/cue-20250630.htm

### September 30, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-11-12, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001193125-25-277466): "As of September 30, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000119312525277466/cue-20250930.htm

### December 31, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-03-16, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001193125-26-108287): "As of December 31, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/cue-20251231.htm

### March 31, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-05-14, last confirmed 2026-05-14.
- SEC Form 10-Q (accession 0001193125-26-224091): "As of March 31, 2026, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000119312526224091/cue-20260331.htm

### June 30, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-08-14, last confirmed 2026-08-14.
- SEC Form 10-Q (accession 0001193125-26-352128): "As of June 30, 2026, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced head and neck squamous cell carcinoma in 2021." https://www.sec.gov/Archives/edgar/data/1645460/000119312526352128/cue-20260630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cue-101.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CUE-101 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cue-101

```bibtex
@misc{secapidev_pdufa_cue_101_20261116,
  title        = {CUE-101 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cue-101}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cue_101_20261116","title":"CUE-101 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cue-101","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
